# EDGAR Filing Document

**Accession Number:** 0001440771
**File Stem:** 0000935836-26-000064
**Filing Date:** 2026-2
**Character Count:** 7984
**Document Hash:** 49797ce9a0e47d50065ef2293dc6df3b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000935836-26-000064.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0000935836-26-000064

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260129

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Stonepine Capital Management, LLC
- **CENTRAL INDEX KEY:** 0001440771

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37846
- **FILM NUMBER:** 26589720

**BUSINESS ADDRESS:**
- **STREET 1:** 2900 NW CLEARWATER DRIVE
- **STREET 2:** SUITE 100-11
- **CITY:** BEND
- **STATE:** OR
- **ZIP:** 97703
- **BUSINESS PHONE:** 541-647-5673

**MAIL ADDRESS:**
- **STREET 1:** 2900 NW CLEARWATER DRIVE
- **STREET 2:** SUITE 100-11
- **CITY:** BEND
- **STATE:** OR
- **ZIP:** 97703
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quoin Pharmaceuticals, Ltd.
- **CENTRAL INDEX KEY:** 0001671502
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23 HATA'AS STREET
- **CITY:** KFAR SABA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 44425
- **BUSINESS PHONE:** 97299741444

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23 HATA'AS STREET
- **CITY:** KFAR SABA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 44425

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellect Biotechnology Ltd.
- **DATE OF NAME CHANGE:** 20160721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cellect Biomed Ltd.
- **DATE OF NAME CHANGE:** 20160406

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Stonepine Capital Management, LLC<br><sub>(Last) (First) (Middle)</sub><br>2900 NW CLEARWATER DRIVE<br>SUITE 100-11<br><sub>(Street)</sub><br>BEND, OR 97703<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Quoin Pharmaceuticals, Ltd. [ QNRX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-01-29 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 3271100<sup>(1)</sup> | I | See Note<sup>(2)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Pre-Funded Warrants | <sup>(3)</sup> | <sup>(3)</sup> | ADS | 81212<sup>(4)</sup> | $0.0001 | I | See Note 2 |
| Series H Warrants | <sup>(5)</sup> | <sup>(5)</sup> | ADS | 121212<sup>(4)</sup> | $9.075 | I | See Note 2 |
| Series I Warrants | <sup>(6)</sup> | <sup>(6)</sup> | ADS | 121212<sup>(4)</sup> | $10.3125 | I | See Note 2 |
| Series J Warrants | <sup>(7)</sup> | <sup>(7)</sup> | ADS | 121212<sup>(4)</sup> | $12.375 | I | See Note 2 |
| Series K Warrants | <sup>(8)</sup> | <sup>(8)</sup> | ADS | 121212<sup>(4)</sup> | $12.375 | I | See Note 2 |

---

### Footnotes:

(1) These Ordinary Shares are held through 93,460 American Depositary Shares ("ADS") of the Issuer. Each ADS represents 35 Ordinary Shares.

(2) The reporting persons are Stonepine Capital Management, LLC ("Stonepine"), Stonepine Capital, L.P. (the "Partnership"), Stonepine GP, LLC ("Stonepine GP") and Jon M. Plexico. Stonepine and Stonepine GP are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and Stonepine GP. The Partnership hold these securities directly for the benefit of its investors. Stonepine and Stonepine GP may be deemed to indirectly beneficially own them as the investment adviser and general partner of the Partnership. Mr. Plexico may be deemed to indirectly beneficially own them as the control person of Stonepine and Stonepine GP. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

(3) The pre-funded warrants are exercisable at any time and have no expiration date.

(4) Each ADS represents 35 Ordinary Shares.

(5) The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.

(6) The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.

(7) The Series J warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.

(8) The Series K warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the Issuer's sale of a Priority Review Voucher (PRV) and (ii) five years from the date of issuance.

**Remarks:**
Stonepine is filing this Form 3 for itself, the Partnership, Stonepine GP and Mr. Plexico. The filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.

**Signature:** /s/ Jon M. Plexico, Managing Mermber of Stonepine Capital Management, LLC  
**Date:** 2026-02-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**